Results 81 to 90 of about 20,292 (247)

Incremental cost-effectiveness of different statin initiation thresholds for primary prevention of ASCVD among PLHIV.

, 2021
Incremental cost-effectiveness of different statin initiation thresholds for primary prevention of ASCVD among PLHIV.
Anchalee Avihingsanon (340691), Pairoj Chattranukulchai (5414063), Matthew G. Law (11413952), Suwimon Khusuwan (11413949), Jeremy Ross (6062105), Sasisopin Kiertiburanakul (427725), David C. Boettiger (11413946), Romanee Chaiwarith (427726)   +7 more
core   +1 more source

Liver function differences in atherosclerotic cardiovascular disease: a multi-ethnic dual-cohort retrospective study

Frontiers in Endocrinology
Background and aimsLiver function plays a pivotal role in the initiation and progression of atherosclerotic cardiovascular disease (ASCVD). Exploring the potential associations between liver function assessment indicators and ASCVD is essential for ...
Yifei Wang, Yifei Wang, Zichen Zhang, Wenbo Ren, Lin Shi, Taiyu Zhai, Jing Huang   +6 more
doaj   +1 more source

MANAGEMENT OF LDL-C IN HIGH RISK FEMALE PATIENTS WITH ASCVD- A CROSS-SECTIONAL STUDY

, 2023
Therapeutic Area: ASCD/CVD in Women Background: The 2018 ACC/AHA guidelines recommend an LDL-C of 70mg/dL as a threshold to initiate non-statin medications in patients with a history of a major ASCVD event.
Kirpal Kochar, Rachel Debenham, Yair Lev, Victoria Starks, Bharaniabirami Rajaram   +4 more
core   +1 more source

Quantification of interaction effect of ASCVD (and/or risk factors) * delayed initiation of SGLT2i.

, 2022
Quantification of interaction effect of ASCVD (and/or risk factors) * delayed initiation of SGLT2i.
Alice P. S. Kong (8473995), Bryan P. Yan (7429832), Wen Sun (273647)   +2 more
core   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5740-5750, July 2026.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Kaplan-Meier survival curves for time-to-ASCVD in Black participants, stratified by CHD PRS category.

, 2023
Kaplan-Meier survival curves for time-to-ASCVD in Black participants, stratified by CHD PRS category.
David Couper (215307), Jamie A. Jarmul (16384688), Vijay Nambi (2156428), Christy L. Avery (8207355), Alanna C. Morrison (7634126), Mark J. Pletcher (10065778), Myriam Fornage (45591), Natalie R. Hasbani (11841733), Paul S. de Vries (8174106), Christie M. Ballantyne (7780190), Allison Bebo (16384685)   +10 more
core   +1 more source

Metabolic dysfunction–associated steatotic liver disease and cardiovascular disease: Emerging insights into the liver–heart axis

Journal of Diabetes Investigation, EarlyView.
Seung‐Hwan Lee
wiley   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6142-6150, July 2026.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause‐Nilsson, Stephen D. Wiviott, Filipe A. Moura, John P. H. Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L. Bhatt, Peter A. Johansson, C. David Sjöström   +12 more
wiley   +1 more source

Mediation effect of platelet indices on the association of daytime nap duration with 10-year ASCVD risk

, 2020
Daytime nap is associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the contribution of platelet to the association of daytime nap with ASCVD remains unclear.
Jiafei Zhang (4094134), Erwei Gao (8391735), Yun Zhou (308977), Jixuan Ma (4526053), Jing Yuan (217967), Tian Li (194773), Weihong Chen (170472), Jian Hou (93442), Lu Wang (45927)   +8 more
core   +1 more source

Event-free survival rates according to ACC/AHA ASCVD risk score (A) and baPWV (B).

, 2022
ACC/AHA ASCVD, American College of Cardiology/American Heart Association atherosclerotic cardiovascular disease; baPWV, brachial-ankle pulse wave velocity.
Tae-Min Rhee (10280577), Hyue Mee Kim (7610087), Hack-Lyoung Kim (654343)   +2 more
core   +1 more source